Iterum Therapeutics PLC (ITRM)

Currency in USD
0.759
-0.021(-2.74%)
Real-time Data·
ITRM Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Trading near 52-week Low
Fair Value
Day's Range
0.7500.800
52 wk Range
0.7503.020
Key Statistics
Prev. Close
0.78
Open
0.79
Day's Range
0.75-0.8
52 wk Range
0.75-3.02
Volume
602.95K
Average Volume (3m)
648.72K
1-Year Change
-37.6%
Book Value / Share
-0.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ITRM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.000
Upside
+822.27%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Iterum Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Iterum Therapeutics PLC Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics PLC Earnings Call Summary for Q4/2024

  • Q4 EPS of -$0.12 beats forecast of -$0.22, stock surges 4.7% to $1.56 in pre-market trading
  • FDA approval of Orlynypa positions Iterum in $40M annual UTI prescription market
  • Q4 net loss narrows to $6.6M, total operating expenses down to $3.7M from $11.4M YoY
  • Cash position of $24.1M as of Dec 2024; company exploring partnerships and capital raising options
  • Revenue forecast to grow to $2.04M by Q4 2025; analyst price targets range from $5 to $10
Last Updated: 07/02/2025, 15:00
Read Full Transcript

Compare ITRM to Peers and Sector

Metrics to compare
ITRM
Peers
Sector
Relationship
P/E Ratio
−1.4x−5.4x−0.5x
PEG Ratio
−0.020.000.00
Price/Book
−11.9x2.9x2.6x
Price / LTM Sales
-2.0x3.2x
Upside (Analyst Target)
-84.8%41.2%
Fair Value Upside
Unlock11.5%6.2%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.000
(+822.27% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.10 / -0.15
Revenue / Forecast
-- / 2.68M
EPS Revisions
Last 90 days

ITRM Income Statement

People Also Watch

1.825
ONDS
-8.75%
17.02
SRPT
+22.80%
0.98
KLTO
-13.12%
0.769
WINT
-16.48%
5.210
MEIP
-12.43%

FAQ

What Stock Exchange Does Iterum Therapeutics Trade On?

Iterum Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Iterum Therapeutics?

The stock symbol for Iterum Therapeutics is "ITRM."

What Is the Iterum Therapeutics Market Cap?

As of today, Iterum Therapeutics market cap is 30.32M.

What Is Iterum Therapeutics's Earnings Per Share (TTM)?

The Iterum Therapeutics EPS (TTM) is -0.93.

When Is the Next Iterum Therapeutics Earnings Date?

Iterum Therapeutics will release its next earnings report on 07 Aug 2025.

From a Technical Analysis Perspective, Is ITRM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Iterum Therapeutics Stock Split?

Iterum Therapeutics has split 1 times.

How Many Employees Does Iterum Therapeutics Have?

Iterum Therapeutics has 9 employees.

What is the current trading status of Iterum Therapeutics (ITRM)?

As of 29 Jul 2025, Iterum Therapeutics (ITRM) is trading at a price of 0.76, with a previous close of 0.78. The stock has fluctuated within a day range of 0.75 to 0.80, while its 52-week range spans from 0.75 to 3.02.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.